Authors

The Importance of Urine Tests for Mutation Detection

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses the importance of having a urine test to detect for cancer mutations.

Thyroid Hormone Receptor and Runx2 Expression in Thyroid Cancer Cells

Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.

The Emerging Role of Obinutuzumab in the Treatment of B-Cell Lymphoid Malignancies

Monoclonal antibodies (mAbs) that target key “restricted” antigens in cancer cells have become an integral part of the management of multiple hematologic and solid tumor malignancies.

Keep Vigilant for Signs of Peripheral Neuropathy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy analyses by cell of origin and by MYC and BCL2 double expression status showed a trend toward improved outcomes of patients treated on the polatuzumab vedotin-containing arm regardless of cell of origin or MYC and BCL2 doubkle expression status.

Regorafenib in the Treatment of Colorectal Cancer

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

Targeting HRAS Mutations With Investigational Tipifarnib May Hold Promise in Some Tumor Types

The high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.

Garon Sheds Light on Next Steps With EGFR-Targeted Agents in NSCLC

Edward B. Garon, MD, discusses the role of EGFR-targeted therapies in the treatment landscape of NSCLC.

Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast Cancer

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

RECORD-3 Study Identifies Poor-Risk Patients With mRCC

James J. Hsieh, MD,&nbsp;discusses differential overall survival (OS) results of the RECORD-3 study based on 3 distinct mRCC molecular subgroups, classified by patients who harbored <em>BAP1</em> and/or <em>PBRM1</em> mutations.

Evolving Paradigms in STS: Perspectives With Shreyaskumar R. Patel and Jonathan C. Trent, MD

Shreyaskumar R. Patel, MD and Jonathan C. Trent, MD discussed the use of trabectedin and the future of the treatment paradigms in soft tissue sarcoma.

Targeting Cancer Stem Cells in the BRIGHTER Trial: A Q&A With Manish A. Shah, MD

Manish A. Shah, MD, a prominent researcher in the gastrointestinal cancer field who is helping to lead the BRIGHTER trial, discussed the ongoing research in an interview with Targeted Oncology.

Combining Immunotherapies With Targeted Therapies and Other Immunotherapies

Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.

The Impact of Breast Cancer Diagnosis on Sexual Dysfunction

Hadeel Assad, MD, hematology/oncology fellow, Providence Hospital and Medical Center, discusses an analysis of the impact of breast cancer diagnosis on sexual dysfunction.

Survival Differences in KRAS/BRAF Mutations in mCRC

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).

Immunotherapy Advances Are Explored in Merkel Cell Carcinoma

Early-stage skin cancers that remain localized are often successfully treated through a variety of surgical techniques as well as radiation therapy, photodynamic therapy, and topical chemotherapy, but advanced cases that are beyond surgery may respond to immunotherapies. This setting will be discussed during the Society for Immunotherapy of Cancer&rsquo;s 34th Annual Meeting.

Post–COVID-19 Infection Remains a Concern in Patients With Cancer

Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.

Mutant-Specific Epidermal Growth Factor Receptor Inhibitors

Treating sensitizing EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) leads to better outcomes compared with standard chemotherapy.

PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibition in Lung Cancer

A review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer.&nbsp;

From the Editor: Targeted Therapy and Immunotherapy Expanding into More Cancer Types